RSC Advances



View Article Online

View Journal | View Issue

PAPER

Check for updates

Cite this: RSC Adv., 2023, 13, 14698

Received 13th April 2023 Accepted 8th May 2023 DOI: 10.1039/d3ra02475j rsc.li/rsc-advances

Introduction

Over the years, organoselenium chemistry has expanded through a multitude of research fields including medicine, catalysis and materials science. Examples of its diverse applicability include antibacterial1 and redox-responsive materials;² utility as catalysts in oxidation, reduction and rearrangement reactions, as well as stereoselective reactions;³ and in dietary supplementation as an essential micronutrient.4 Taking into consideration the nutritional and biochemical properties of naturally abundant organoselenium compounds like selenocysteine, selenomethionine and selenium as an element itself, one of the leading directions of development in the field is medicinal chemistry. As one of the most evaluated small antioxidant molecules, organoselenium compounds can be considered leading players in the race for market-approved drugs. The ability to mimic the antioxidant selenoenzyme glutathione peroxidase (GPx) determines its high redox-modulating properties.⁵ Over the years, they have also been proven to exhibit various

Facile synthesis of chiral phenylselenides as novel antioxidants and cytotoxic agents[†]

Anna Laskowska, ^a Agata J. Pacuła-Miszewska, 🕩 *^a Magdalena Obieziurska-Fabisiak, ^a Aneta Jastrzebska,^b Katarzyna Gach-Janczak,^c Anna Janecka^c and Jacek Ścianowski 🕩 a

Organoselenium compounds are well-known for their unique biological properties, including antioxidant, anticancer and anti-inflammatory. They result from the presence of a particular Semojety enclosed in a structure that provides physicochemical features necessary for effective drug-target interactions. Looking for a proper drug design that considers the influence of each structural element has to be conducted. In this paper, we have synthesized a series of chiral phenylselenides, possessing an additional N-substituted amide moiety, and evaluated their antioxidant and anticancer potential. The presented derivatives, as a group of enantiomeric and diastereomeric pairs, enabled a thorough investigation of the 3D structure-activity dependence in correlation with the presence of the phenylselanyl group as the potential pharmacophore. The Nindanyl derivatives possessing a cis- and trans-2-hydroxy group were selected as the most promising antioxidants and anticancer agents.

> biological activities including anticancer, anti-inflammatory, and antibacterial.6-11 However, issues associated with bioavailability and side effects remain major obstacles in the design of safe Se-therapeutics.

> Since the discovery of the well-known peroxide scavenger ebselen (N-phenylbenzisoselenazol-3(2H)-one) a lot has been accomplished in the search for the ideal structural modifications that would maximize the therapeutic potential of the Se-moiety and reduce its toxicity.12-16 Modifying the primary benzisoselenazolone core can significantly affect the physicochemical properties of the molecule, thus changing the pharmacokinetics and biochemical outcome of the potential drug. We have recently observed that in some cases, the exchange of the Se-N for a Se-Car bond and incorporation of an additional aromatic ring enhances the cytotoxic activity of chiral N-terpene benzisoselenazolones 1 and 3.17 The IC₅₀ values decreased approximately six and twelve times for Nmenthyl 2 and N-caranyl phenylselenide 4, respectively (Fig. 1).

> These results prompted us to investigate if the presence of the phenylselanyl group can enhance the antiproliferative effect. There are few methods that enable to obtain unsymmetrical phenylselenides with a secondary amide group: starting from corresponding benzisoselenazolones through the reaction with Grignard reagent (method A);18 based on the Ru-catalyzed selenation of benzamides (method B);19 and Cucatalyzed nucleophilic substitution of o-iodobenzamides (method C), previously reported by our research group¹⁷ (Scheme 1). Herein, we have utilized one of the known

^aDepartment of Organic Chemistry, Faculty of Chemistry, Nicolaus Copernicus University, 7 Gagarin Street, 87-100, Torun, Poland . E-mail: pacula@umk.pl

^bDepartment of Analytical Chemistry and Applied Spectroscopy, Faculty of Chemistry, Nicolaus Copernicus University, 7 Gagarin Street, 87-100, Torun, Poland

Department of Biomolecular Chemistry, Faculty of Medicine, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215, Lodz, Poland

[†] Electronic supplementary information (ESI) available: ¹H, ¹³C and ⁷⁷Se NMR spectra of phenylselenides 6-19 are available. See DOI: https://doi.org/10.1039/d3ra02475j



ig. 1 *N*-terpene phenylselenides with enhanced bio-activity.



Scheme 1 Methods for the preparation of diphenylselenides monosubstituted with *o*-amido function.

protocols to synthesize a series of chiral unsymmetrical diphenyl selenides and evaluated their antioxidant and anticancer activity. The presented derivatives are pairs of enantiomers and diastereoisomers, which additionally allows determining whether the molecule's spatial structure can, in this case, influence the drug-target interaction and increase the therapeutic potential.

Results and discussion

The first stage of the research involved the synthesis of phenylselenides 6–19. For this purpose, we have slightly modified the procedure proposed by Młochowski and co-workers (Method A, Scheme 1). To a solution of phenyl



Scheme 2 Synthesis of phenylselenides 6-19.

magnesium bromide, formed by refluxing PhBr and Mg^0 in diethyl ether, appropriate *N*-substituted benzisoselenazolone 5 (obtained previously through the reaction of 2-(chloroseleno)benzoyl chloride with an appropriate enantiomerically pure amine²⁰) dissolved in Et₂O or THF was added (Scheme 2).

Due to low solubility of the starting materials **5**, the reaction time had to be elongated to 24 h. All products **6–19** were obtained in good yields (Scheme 3). Surprisingly, our recently reported protocol (Method C, Scheme 1) was not efficient for these type of bulky substrates, *e.g.* compound **15** was obtained in only 38% yield, contrary to Method A which furnished the final phenylselenide **15** in 92%.

The antioxidant activity of all synthesized compounds was evaluated by two assays. First, by the procedure presented by Iwaoka and co-workers.²¹ Herein, the particular selenide **6–19**, serving as the Se-catalyst, is first oxidized by hydrogen peroxide to the corresponding selenooxide **20**. Then, the activated catalyst **20** transforms the dithiol DTT^{red} to the disulfide DTT^{ox}. The progress of the reaction, disappearance of signals correlated with DTT^{red} and appearance of those associated with DTT^{ox}, is monitored by the changes in ¹H NMR spectra in specific time intervals. Unfortunately, in all cases, the conversion was less efficient than in the presence of ebselen (Table 1).

In the second study, the popular 2,2'-diphenyl-1picrylhydrazyl (DPPH[•]) radical scavenging assay (RSA) was used to measure the total antioxidant capacity for all obtained compounds. It has been applied to quantify antioxidant activity in many samples using antioxidant standards such as ascorbic acid, butylated hydroxyl toluene, a-tocopherol, butylated hydroxyl anisole, gallic acid, and trolox.²² The results of this assay were expressed as IC_{50} values (Table 2). The IC_{50} value is defined as the antioxidant concentration required to reduce 50% of the initial DPPH concentration.²³ The percentage of inhibition against the DPPH radical was



Scheme 3 Synthesized phenylselenides 6-19



Se-catalyst [0.1 eq.]	Remaining DTT ^{red} [%]				
	5 min	15 min	30 min	60 min	
Phenylselenides					
6/7	87	86	86	85	
8/9	91	85	81	76	
10/11	88	84	79	75	
12/13	88	85	83	83	
14/15	89	86	84	82	
16/17	87	85	83	81	
18/19	88	85	83	80	
Ebselen	75	64	58	52	

 Table 2
 Results collected from the DPPH radical scavenging assay

$\mathrm{IC50}_{\mathrm{DPPH}} \left[\mu \mathrm{mol} \ \mathrm{L}^{-1} \right]$
7149.2
1752.6
1714.3
1715.1
1704.7
6470.4
1429.3

calculated with the following equation: inhibition (%) = $((A - B)/A) \times 100$, where *A* and *B* are the absorptions of the blank samples and working standards. The DPPH' test is based on

Table 3	The	antiproliferative	activity of	compounds	6–19
---------	-----	-------------------	-------------	-----------	------

	$\mathrm{IC}_{50}\left[\mu\mathrm{M} ight]\pm\mathrm{SEM}$			
Compound	HL-60	MCF-7		
6	>150	>150		
7	>150	>150		
8	>150	>150		
9	>150	>150		
10	>150	>150		
11	>150	>150		
12	>150	>150		
13	>150	>150		
14	>150	>150		
15	>150	>150		
16	>150	>150		
17	>150	16.65 ± 1.36		
18	69.50 ± 0.71	83.38 ± 1.94		
19	55.45 ± 3.01	63.75 ± 0.35		

spectrophotometric mixed mode assays based on single electron transfer (SET), hydrogen atom transfer (HAT), and protoncoupled electron transfer (PCET) mechanisms. The DPPH radical can only be dissolved in organic media thus, this assay has a higher affinity toward lipophilic than hydrophilic antioxidants. The highest antioxidant capacity was observed for the *trans*-indanyl diastereoisomers **18/19**. Surprisingly, the *cis*indanyl conformers **16/17** were approximately 4 times less active.

Next, the antiproliferative activity of derivatives **6–19** was evaluated towards leukemia HL-60 and breast cancer MCF-7 cell lines.²⁴ The highest cytotoxic potential was observed for the indanyl phenylselenides possessing the *cis* (**17**) and *trans* (**18**, **19**) 2-hydroxy group (Table 3).

As presented in our previous papers,²⁰ the presence of the indanyl substituent attached to the nitrogen atom of benzisoselenazolones and corresponding diselenides also enhances the cytotoxic effect. A comparison of all 3 types of indanyl Se-derivatives is presented in Table 4. Benzisoselenazolones (A–D) show a moderate cytotoxic activity and it is similar towards both tested cell lines with IC₅₀ values ranging from 7.9 \pm 0.3 to 28.8 \pm 2.1 μ M. In the case of all diselenides (A–D), the cytotoxicity against MCF-7 cells is low (IC₅₀ > 100 μ M), whereas HL-60 cell line is far more sensitive (IC₅₀ < 20 μ M).

Phenylselenides with a *trans*-hydroxy group (C and D) on the indanyl scaffold present similar low activity to both cell lines, however, in the case of *cis*-hydroxy-indanyl derivative B the MCF-7 cell line is inhibited more effectively (IC₅₀ = 16.7 \pm 1.4 μ M). Thus, bio-selectivity seems to be strongly related to the type of the Se-moiety, regardless of the chirality of the indanyl substituent.

Table 4 The antiproliferative activity of N-indanyl Se-derivatives

	HO,, Organoselenium scaffold		HO μ C IC ₅₀ [μΝ	HO,, D A]± SEM
	A		В	
Se-derivative	MCF-7	HL-60	MCF-7	HL-60
Phenylselenide	>150	>150	16.6 ± 1.3	>150
Benzisoselenazolone	14.9 ± 0.9	7.9 ± 0.3	28.8 ± 2.1	28.2 ± 1.1
Diselenide	>100	20.0 ± 0.1	>100	$\textbf{21.7} \pm \textbf{2.1}$
	С		D	
Se-derivative	MCF-7	HL-60	MCF-7	HL-60
Phenylselenide	83.3 ± 1.9	69.5 ± 0.7	63.7 ± 0.3	55.4 ± 3.0
Benzisoselenazolone	22.1 ± 3.1	11.4 ± 1.0	27.6 ± 2.1	16.2 ± 1.8
Diselenide	>100	12.4 ± 0.3	>100	13.0 ± 0

Conclusions

In conclusion, we have developed a facile synthesis of chiral unsymmetrical diphenylselenides possessing an additional *o*amide group on one of the aromatic rings. The derivatives were *N*-substituted with chiral groups forming a series of enantiomeric and diastereomeric pairs. Although the phenylselanyl group seems not to be improving the bio-activity of the organoselenium derivatives, in contrary to corresponding benzisoselenazolones with Se–N moiety and diselenides equipped with a Se–Se bond, the obtained results confirm that also for these type of Se-derivatives, the presence of the *N*-indanyl scaffold enhance the antioxidant and anticancer properties. Thus, the *cis-* and *trans*-indanyl moiety can be considered a pharmacophore necessary for the optimal drug–target interaction.

Experimental

General

NMR spectra were recorded on Bruker Avance III/400 or Bruker Avance III/700 (Karlsruhe, Germany) for ¹H and 176.1 MHz or 100.6 MHz for ¹³C (see ESI[†]). Chemical shifts were recorded relative to SiMe₄ (δ 0.00) or solvent resonance (CDCl₃ δ 7.26, CD₃OD δ 3.31). Multiplicities were given as: s (singlet), d (doublet), dd (double doublet), ddd (double double doublet), t (triplet), dt (double triplet), and m (multiplet). The ⁷⁷Se NMR spectra were recorded on Bruker Avance III/400 or Bruker Avance III/700 with diphenyl diselenide as an external standard. NMR spectra were carried out using ACD/NMR Processor Academic Edition. Melting points were measured with a Büchi Tottoli SPM-20 heating unit (Büchi Labortechnik AG, Flawil, Switzerland) and were uncorrected. Elemental analyses were performed on a Vario MACRO CHN analyzer. Optical rotations were measured in 10 mm cells with a polAAr 3000 polarimeter. Column chromatography was performed using Sigma Aldrich 60 Å (52-73 A) 63-200 µm silica gel (Merck, Darmstadt, Germany).

General procedure for the synthesis of phenylselenides 6-19

To a suspension of elemental magnesium in diethyl ether, phenyl bromide was slowly added (during this time, the mixture was continuously heated to 40 °C). The reaction mixture was stirred and refluxed until all magnesium was dissolved (≈ 2 h) at 40 °C under anaerobic conditions. Appropriate *N*-substituted benzisoselenazol-3(2*H*)-one, dissolved in diethyl ether or THF THF (Et₂O: 6, 7, 8, 9, 12, 13, 14, 15; THF: 10, 11, 16, 17, 18, 19) was slowly added. The reaction was stirred at 40 °C for 24 h, poured on water, and extracted with DCM. The combined organic layers were dried over anhydrous magnesium sulfate and evaporated. The crude product was purified by column chromatography (silica gel, DCM). Characterization of all obtained products is presented in ESI file.†

Antioxidant activity assays

DTT-assay. To a solution of compounds **6–19** (0.015 mmol) and dithiothreitol DTT^{red} (0.15 mmol) in 1.1 mL of CD₃OD, 30% H_2O_2 (0.15 mmol) was added. ¹H NMR spectra were measured right after the addition of hydrogen peroxide and then in specific time intervals. The concentration of the substrate was determined according to the changes in the integration on the ¹H NMR spectra.²¹

The 2,2'-diphenyl-1-picrylhydrazyl (DPPH') method. The antioxidant capacity of each compound was determined by spectrophotometric DPPH' method. The discussed compounds 6–19 were dissolved in methanol (5 mL), next different values of the obtained solutions were added to 0.5 mL DPPH methanolic solution (0.30 mmol L⁻¹) and made up to 2.5 mL with methanol. The mixture was shaken vigorously and left in darkness for 15 min. The absorbance was measured at 517 nm against a reagent blank (2 mL of methanol with 0.5 mL of DPPH methanolic solution) using a 1 cm quartz cell in a Shimadzu UV-1601 spectrophotometer.

RSC Advances

The 50% DPPH' inhibition (IC50_{DPPH}) was calculated based on linear regression analyses (the relationship curve of %DPPH scavenging *versus* concentrations of the respective sample).

The calibration curve was prepared using working solutions of 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (trolox) in methanol between 0.02–0.10 mmol mL⁻¹ and resulted in the equation: $\text{\%DPPH}^{\cdot} = 0.5155C_{\text{TE}} + 1.8291$.

MTT viability assay. The MTT (3-(4,5-dimethyldiazol-2-yl)-2,5 diphenyl tetrazolium bromide) assay, which measures the activity of cellular dehydrogenases, was based on the method of Mosmann.²⁴ Briefly, cells were seeded into 24-well plates (about 8×10^4 cells per mL) and then left to adhere and grow for 24 h. Subsequently, the tested compounds in the medium were added to a final concentration of 0-150 µM for 48 h, followed by the addition of 100 μ L MTT, 5 mg mL⁻¹ in PBS, for the next 2 h. Then, the plates were centrifuged, the supernatant was discarded and remaining insoluble formazan crystals were dissolved in 1 mL DMSO. The absorbance of the blue formazan product was measured at 560 nm using FlexStation 3 Multi-Mode Microplate Reader (Molecular Devices, LLC, CA, USA) and compared with control (untreated cells). All experiments were performed three times in triplicate. The concentration of the tested compounds required to inhibit cell viability by 50% (IC₅₀) was calculated from concentration-response curves.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Financial support from the NCU research grant "Excellence Initiative – Debuts – III edition" number 03.01.00002702, Zad.6. IDUB/Debiuty_3_ and program for financing the costs of publication of doctoral students under the program "Initiative of excellence - Research University".

References

- 1 M. Liu, X. Zhang, S. Chu, Y. Ge, T. Huang, Y. Liu and L. Yu, *Chin. Chem. Lett.*, 2022, **33**, 205.
- 2 Q. Li, Y. Zhang, Z. Chen, X. Pan, Z. Zhang, J. Zhu and X. Zhua, *Org. Chem. Front.*, 2020, 7, 2815.
- 3 F. V. Singh and T. Wirth, Catal. Sci. Technol., 2019, 9, 1073.
- 4 C. M. Weekley and H. H. Harris, *Chem. Soc. Rev.*, 2013, 42, 8870.
- 5 M. Obieziurska-Fabisiak, A. J. Pacuła-Miszewska, A. Laskowska and J. Ścianowski, *Arkivoc*, 2022, v, 212.

- 6 J. Pacuła, F. Mangiavacchi, L. Sancineto, E. J. Lenardao, J. Ścianowski and C. Santi, *Curr. Chem. Biol.*, 2015, **9**, 97.
- 7 F. V. Singh and T. Wirth, Synthesis of Organoselenium Compounds with Potential Biological Activities, in *Organoselenium Compounds in Biology and Medicine: Synthesis, Biological and Therapeutic Treatments*, Royal Society of Chemistry, London, UK, 2017, p. 77.
- 8 H. Chuai, S. Q. Zhang, H. Bai, J. Li, Y. Wang, J. Sun, E. Wen, J. Zhang and M. Xin, *Eur. J. Med. Chem.*, 2021, 223, 113621.
- 9 W. Hou, H. Dong, X. Zhang, Y. Wang, L. Su and H. Xu, *Drug Discovery Today*, 2022, 27, 2268.
- L. Sancineto, A. Mariotti, L. Bagnoli, F. Marini, J. Desantis, N. Iraci, C. Santi, C. Pannecouque and O. J. Tabarrini, *J. Med. Chem.*, 2015, 58, 9601.
- 11 D. Krasowska, N. Iraci, C. Santi, J. Drabowicz, M. Cieslak, J. Kaźmierczak-Barańska, M. Palomba, K. Królewska-Golińska, J. Magiera and L. Sancineto, *Molecules*, 2019, 24, 2914.
- 12 P. Santofimia-Castaño, A. Izquierdo-alvarez, I. Casa-resino, A. Martinez-ruiz, M. Perez-lopez, J. C. Portilla, G. M. Salido and A. Gonzalez, *Toxicology*, 2016, **74**, 357.
- 13 G. K. Azad and R. Tomar, Mol. Biol. Rep., 2014, 41, 4865.
- 14 J. L. Benelli, V. R. Poester, L. S. Munhoz, A. M. Melo, M. R. Trapaga, D. A. Stevens and M. O. Xavier, *Med. Mycol.*, 2021, 59, 409.
- 15 M. J. Parnham and H. Sies, *Biochem. Pharmacol.*, 2013, **86**, 1248.
- 16 C. Santi, C. Scimmi and L. Sancineto, *Molecules*, 2021, 26, 4230.
- M. Obieziurska-Fabisiak, A. J. Pacuła, L. Capoccia, J. Drogosz-Stachowicz, A. Janecka, C. Santi and J. Ścianowski, *Molecules*, 2020, 25, 3354.
- 18 R. Lisiak and J. Młochowski, Synth. Commun., 2009, 39, 3141.
- 19 W. Ma, Z. Weng, X. Fang, L. Gu, Y. Song and L. Ackermann, *Eur. J. Org. Chem.*, 2019, **1**, 41.
- 20 A. Laskowska, A. J. Pacuła-Miszewska, M. Obieziurska-Fabisiak, J. Drogosz-Stachowicz, A. Janecka, A. Wojtczak and J. Ścianowski, *Materials*, 2022, 15, 2068.
- 21 F. Kumakura, B. Mishra, K. I. Priyadarsini and M. Iwaoka, *Eur. J. Org. Chem.*, 2010, **3**, 440.
- 22 F. Martinez-Morales, A. J. Alonso-Castro, J. R. Zapata-Morales, C. Carranza-Alvarez and O. H. Aragon-Martinez, *Chem. Pap.*, 2020, **74**, 3325.
- 23 B. Brummelhaus de Menezes, L. Mironuk Frescura,
 R. Duarte, M. A. Villetti and M. Barcellos da Rosa, *Anal. Chim. Acta*, 2021, 1157, 338398.
- 24 T. Mosmann, J. Immunol. Methods, 1983, 65, 55.